ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2903 • 2018 ACR/ARHP Annual Meeting

    Single Cell Association Testing Identifies an Expanded Th1-Skewed Cytotoxic Effector CD4+ T Cell Subset in Rheumatoid Arthritis

    Chamith Fonseka1, Deepak Rao2, Nikola Teslovich3, Ilya Korsunsky4, Susan Hannes5, Kamil Slowikowski1, Michael Gurish6, Laura T. Donlin7, James A. Lederer8, Michael Weinblatt9, Elena Massarotti9, Jonathan Coblyn9, Simon Helfgott10, Derrick J. Todd11, Vivian P. Bykerk12, Elizabeth Karlson13, Joerg Ermann14, Yvonne C. Lee15, Michael Brenner16 and Soumya Raychaudhuri1,17, 1Divisions of Genetics and Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Human Immunology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Division of Genetics and Rheumatology, Department of Medicine, Harvard Medical School, Boston, MA, 4Division of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Division of Genetics, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 6Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 7Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, 8Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 9Brigham and Women's Hospital, Boston, MA, 10Division of Rheumatology, Brigham and Women’s Hospital, Boston, MA, 11Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 12Deptartment of Rheumatology, Hospital for Special Surgery, New York, NY, 13Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 14Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 15Northwestern University Feinberg School of Medicine, Chicago, IL, 16Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 17Program in Medical and Population Genetics, Broad Institute, Boston, MA

    Background/Purpose: Defining the precise CD4+ T cell subsets that are dysregulated in RA patients is critical to deciphering pathogenesis. Here we present Mixed effects modeling…
  • Abstract Number: 2904 • 2018 ACR/ARHP Annual Meeting

    Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients and Healthy Controls

    Ralf G. Thiele1, Yahui Grace Chiu2, Nelson Huertas3, Dongge Li4, Changyong Feng5, Sharon Moorehead6, Cristy Bell7 and Christopher T. Ritchlin8, 1Division of Rheumatology, University of Rochester Medical Center, Rochester, NY, 2Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, 3Department of Medicine, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, 4Allergy, Immunology and Rheumatology, Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, 5Statistics, University of Rochester, Rochester, NY, 6Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, 7Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 8Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY

    Background/Purpose: The events that underlie the transition from psoriasis (Ps) to psoriatic arthritis (PsA) are not well understood, although up to 30% of Ps patients…
  • Abstract Number: 2905 • 2018 ACR/ARHP Annual Meeting

    Ultrasound Diagnosis of Large Vessel Inflammation in New-Onset Treatment-Naïve GCA Patients Using Fluorine-18-Fluorodeoxyglucose PET/CT As the Reference Standard – a Prospective Study of 86 Patients Suspected of GCA

    Berit Dalsgaard Nielsen1, Ib Tønder Hansen2, Kresten Krarup Keller3, Philip Therkildsen4, Lars Christian Gormsen5 and Ellen-Margrethe Hauge6, 1Clnical Medicine, Department of Clinical Medicine, Aarhus University Hospital, Århus N, Denmark, 2Clinical Medicine, Department of Clinical Medicine, Aarhus University Hospital, Århus N, Denmark, 3Department of Rheumatology, Aarhus University Hospital, Aarhus, Aarhus, Denmark, 4Department of Rheumatology, Aarhus University Hospital, Aarhus C, Denmark, 5Nuclear Medicine and PET Center, Department of Nuclear Medicine and PET Center, Aarhus University Hospital, Århus C, Denmark, 6Department of Rheumatology, Aarhus University Hospital, Department of Clinical Medicine, Aarhus, Denmark

    Background/Purpose: EULAR recommendations suggest diagnostic imaging in all GCA suspects. Vascular ultrasound (US) is cheap, readily available and the recommended first line examination in cranial…
  • Abstract Number: 2906 • 2018 ACR/ARHP Annual Meeting

    Synovitis Focused Ultrasound in Rheumatoid Arthritis: A Joint Reduction Strategy

    Daniel Kuo1, Gurjit Kaeley2, Ami Ben-Artzi3, Jenny Brook4, Astrid Floegel-Shetty4, David Elashoff4 and Veena K. Ranganath1, 1Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 2Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL, 3Rheumatology, Cedars Sinai Medical Center, Beverly Hills, CA, 4Department of Medicine Statistics Core, UCLA David Geffen School of Medicine, Los Angeles, CA

    Background/Purpose: Musculoskeletal ultrasound is increasingly being used as a tool to assess inflammatory burden in rheumatoid arthritis (RA). Ultrasound-based outcome measures include power Doppler (PD)…
  • Abstract Number: 2907 • 2018 ACR/ARHP Annual Meeting

    Comparison of the Joints Ultrasonography in the Patients with Rheumatoid Arthritis Treated By Biological Agents and the Corresponding Synovial Histological Findings

    Asami Abe1, Hajime Ishikawa2 and Kunihiko Wakaki3, 1Rheumatology, Niigata Rheumatic Center, Shibata, Japan, 2Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan, 3Pathology, Niigata Prefectural Shibata Hospital, Shibata, Japan

    Comparison of the joints ultrasonography in the patients with rheumatoid arthritis treated by biological agents and the corresponding synovial histological findings Background/Purpose: In the treatment…
  • Abstract Number: 2908 • 2018 ACR/ARHP Annual Meeting

    Agreement between Ultrasound and Whole Body Magnetic Resonance Imaging Assessment of Joint Inflammation and Enthesitis in Rheumatoid Arthritis Patients

    Sin Ngai Ng1, Mette Bjørndal Axelsen2, Mikkel Østergaard3, Iris Eshed4, Merete Lund Hetland2, Jakob M. Møller5, Susanne J Pedersen6,7 and Lene Terslev8, 1Medicine, Queen Elizabeth Hospital , Hong Kong, Hong Kong, Hong Kong, 2Copenhagen Center for Arthritis Research, Copenhagen, Denmark, 3Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup Copenhagen Center for Arthritis Research, Copenhagen, Denmark, 4Department of Radiology, Sheba Medical Center, Israel, Tel Hashomer, Israel, 5Dept. of Radiology, Copenhagen University Hospitals, Herlev and Gentofte, Copenhagen, Denmark, 6Depart of Rheumatology VRR, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Denmark, 7Dept. of Rheumatology, Copenhagen Center for Arthritis Research, Copenhagen, Denmark, 8Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark

    Background/Purpose: To evaluate the agreement between ultrasound (US), whole body magnetic resonance imaging (WBMRI) and clinical assessment of joint inflammation and enthesitis in rheumatoid arthritis…
  • Abstract Number: 2909 • 2018 ACR/ARHP Annual Meeting

    Diagnostic and Prognostic Value of Ultrasound Compared with Plain Radiography in Knee Osteoarthritis

    Annie Yang1, Fernando Bomfim2, Kristen Lee2, Mukundan Attur3, Steven B. Abramson4 and Jonathan Samuels5, 1Department of Medicine, NYU Langone Health, New York, NY, 2NYU Langone Health, New York, NY, 3Rheumatology, NYU Langone Health, New York, NY, 4Dept of Medicine, NYU Langone Health, New York, NY, 5Department of Medicine, Divison of Rheumatology, NYU Langone Health, New York, NY

    Background/Purpose: Plain radiography of knee osteoarthritis (OA) has inherent diagnostic and prognostic limitations, especially in early disease.  Ultrasound (US) examination sheds light on disease activity…
  • Abstract Number: 2910 • 2018 ACR/ARHP Annual Meeting

    Development of a Rheumatoid Arthritis Global Outcome Measure to Enable Comparisons of Patient Experiences across Treatment Arms in Randomized Clinical Trials

    Liana Fraenkel1, W. Benjamin Nowell2, Carole Wiedmeyer2, Zhenglin Wei3, Kaleb Michaud4, Tuhina Neogi5, Christine Ramsey1 and David Broniatowski3, 1Yale University School of Medicine, New Haven, CT, 2Global Healthy Living Foundation, Upper Nyack, NY, 3George Washington University, Washington, DC, 4Rheumatology, University of Nebraska Medical Center, Omaha, NE, 5Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA

    Background/Purpose: Randomized controlled trials currently report benefits and adverse events (AEs) separately, and therefore do not permit comparisons of patients’ overall experiences on one treatment…
  • Abstract Number: 2911 • 2018 ACR/ARHP Annual Meeting

    Patient-Reported Outcomes Measurement Information System (PROMIS®) Global Health Short Form Is Responsive to Patient Reported Changes in SLE Health Status

    Shanthini Kasturi1, Jackie Szymonifka2, Jessica R. Berman3, Kyriakos A. Kirou3, Alana B. Levine3, Lisa R Sammaritano4 and Lisa A. Mandl4, 1Medicine/Rheumatology, Tufts Medical Center, Boston, MA, 2Hospital for Special Surgery, New York, NY, 3Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 4Hospital for Special Surgery/Weill Cornell Medicine, New York, NY

    Background/Purpose: The accurate and efficient serial measurement of patient centered outcomes is a priority in the clinical care of SLE. Patient-Reported Outcomes Measurement Information Systems…
  • Abstract Number: 2912 • 2018 ACR/ARHP Annual Meeting

    Lupus Flare Activity from the Patient Perspective

    Winnie Nelson1, Patricia Katz2, R. Paola Daly3, Lauren Topf3, Erin Connolly-Strong4 and Michael Reed5, 1Health Economics and Outcomes Research, Mallinckrodt Pharmaceuticals, Bedminster, NJ, 2University of California San Francisco, San Francisco, CA, 3Lupus Foundation of America, Washington, DC, 4Mallinckrodt ARD, Inc., Bedminster, NJ, 5Vedanta Research, Chapel Hill, NC

    Background/Purpose: Lupus patients may experience flares in disease activity that require rapid management. This study describes the experience, identification, and management of a flare from…
  • Abstract Number: 2913 • 2018 ACR/ARHP Annual Meeting

    A Draft Modified Core Domain Set for Patient-Reported Outcomes (PRO) in Patients with Idiopathic Inflammatory Myopathies (IIM): An Omeract Report

    Malin Regardt1,2, Christopher A. Mecoli3,4,5, Jin Kyun Park6,7,8,9,10,11,12,13,14, Merrilee Needham15, Ingrid De Groot16, Catherine Sarver17, Ingrid E. Lundberg18, Beverly Shea19, Marianne De Visser20, Yeong Wook Song13, Clifton O. Bingham III21, Lisa Christopher-Stine22,23,24 and Helene Alexanderson25, 1Learning, Informatics,Management and Ethics, Karolinska institutet, Stockholm, Sweden, 2Function Area Occupational Therapy and Physical Therapy, Karolinska University Hospital, Stockholm, Sweden, 3Johns Hopkins University School of Medicine, Baltimore, MD, 4Internal Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, 5Rheumatology, Johns Hopkins University, Baltimore, MD, 6Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea, Republic of (South), 7Division of Rheumatology, Seoul National University Hospital, Seoul, Korea, Republic of (South), 8Department of Molecular medicine and biopharmaceutical science, Seoul National University, seoul, Korea, Republic of (South), 9Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), 10[email protected], Division of Rheumatology, Seoul National University Hospital, Seoul, Korea, Republic of (South), 11Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), 12Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, Korea, Republic of (South), 13Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South), 14Department of Molecular Medicine and Biopharmaceutical Sciences, BK21 plus Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy, Seoul National University, Seoul, Korea, Republic of (South), 15Murdoch University, Perth, Australia, 16patient research partner, Rotterdam, Netherlands, 17patient research partner, maryland, MD, 18Department of Medicine, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden, 19Bruyere Research Institute, Ottawa, ON, Canada, 20Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands, 21Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 22Ste 4100 Rm 409, Johns Hopkins University School of Medicine, Baltimore, MD, 23Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 24Medicine and Neurology, Johns Hopkins University, Baltimore, MD, 25Department of NVS, Division of Physical Therapy, Karolinska Institutet, Huddinge, Sweden

    A Draft Modified Core Domain Set for Patient-Reported Outcomes (PRO) in Patients with Idiopathic Inflammatory Myopathies (IIM): An OMERACT ReportBackground/Purpose: The OMERACT Myositis special interest…
  • Abstract Number: 2914 • 2018 ACR/ARHP Annual Meeting

    Examination of Psychometric Properties of the Patient-Reported Outcomes Measurement Information System Fatigue 4-Item Short Form in Psoriatic Arthritis

    Patricia Katz1,2, Alexis Ogdie3, Evo Alemao4, Jayanti Mukherjee4 and Kaleb Michaud2,5, 1Forward/National Data Bank for Rheumatic Diseases, Wichita, KS, 2University of California San Francisco, San Francisco, CA, 3Hospital of the University of Pennsylvania, Philadelphia, PA, 4Bristol-Myers Squibb, Princeton, NJ, 5Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: PROMIS (Patient-Reported Outcomes Measurement Information System) measures have not been tested in psoriatic arthritis (PsA). We examined the reliability, validity and responsiveness of the…
  • Abstract Number: 2915 • 2018 ACR/ARHP Annual Meeting

    Can Passively-Collected Phone Behavior Determine Rheumatic Disease Activity?

    Kaleb Michaud, Sofia Pedro and Rebecca Schumacher, FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS

    Background/Purpose: Advances in reality mining combined with the pervasive use of smart phones have shown measurable changes in phone behavior due to changes in health.…
  • Abstract Number: 2916 • 2018 ACR/ARHP Annual Meeting

    New JADAS10- and cJADAS10-Based Cutoffs for Juvenile Idiopathic Arthritis Disease Activity States: Validation in a Multinational Dataset of 4830 Patients

    Alessandro Consolaro1,2, Chiara Trincianti1, Pieter van Dijkhuizen3, Giedre Januskeviciute4, Gabriella Giancane5, Alessandra Alongi1, Joost Swart3, Nicola Ruperto6,7 and Angelo Ravelli2,8, 1University of Genova, Genova, Italy, 2Clinica Pediatrica - Reumatologia, Istituto Giannina Gaslini, Genova, Italy, 3UMC Utrecht, Wilhelmina Children’s Hospital, Utrecht, Netherlands, 4Istituto Giannina Gaslini, Genova, Italy, 5Clinica Pediatrica - Reumatologia, Istituto Giannina Gaslini, Genoa, Italy, 6Universita di Genova Pediatria II, Genova, Italy, 7Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, 8University of Genova, Genoa, Italy

    Background/Purpose: The Juvenile Arthritis Disease Activity Score (JADAS) and its clinical version excluding the acute phase reactant (cJADAS) were developed for measuring disease activity in…
  • Abstract Number: 2917 • 2018 ACR/ARHP Annual Meeting

    Multiplex Serum Biomarker Analysis before and during Therapy with Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis

    Tanja Hinze1, Christoph Kessel1, Claas Hinze1, Julia Seibert2, Hermann Gram2 and Dirk Foell3, 1Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, 2Novartis, Basel, Switzerland, 3Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany

    Background/Purpose: Canakinumab (CAN), a monoclonal anti-interleukin (IL)-1β antibody, is approved for the treatment of systemic juvenile idiopathic arthritis (SJIA). CAN-treated patients with SJIA showed a…
  • « Previous Page
  • 1
  • …
  • 1196
  • 1197
  • 1198
  • 1199
  • 1200
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology